Introduction
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for more than 80% of all lung cancer cases. About 60% of NSCLC cases present with metastatic disease and 5-year survival remains poor. [1] Standard of care for stage four, driver mutation-negative NSCLC till now remained platinum doublet therapy with 1-year median survival. [2] After disease progression, few treatment options were available, i.e., docetaxel and pemetrexed (pemetrexed for the treatment of only adenocarcinoma). There was an unmet need for second-line treatment options that will improve overall survival (OS) with a better side-effect profile.
In a multicohort Phase 1 study involving previously untreated patients with NSCLC (CheckMate 012), 12 durable responses were seen in patients who received nivolumab. Median progression-free survival (PFS) was 10.6 months, and response rates were 50%. Clinical activity was not only seen in patients with increasing Programmed Death Ligand-1 (PDL-1) levels but also with a low-PDL-1 expression level or with no PDL-1 expression.
In two pivotal CheckMate trials, [3, 4] comparing nivolumab to docetaxel in the second-line setting, nivolumab resulted in longer OS in both squamous and nonsquamous advanced NSCLC. Nivolumab was the first checkpoint inhibitor that was compared to docetaxel and approved as second-line option for both squamous and adenocarcinoma [ Table 1 ].
After the two pivotal CheckMate trials, [3, 4] nivolumab became standard of care in second-line setting for both histological subtypes (adenocarcinoma and squamous cell carcinoma) irrespective of PDL-1 status and showed a survival benefit in previously treated patients.
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All of the patients included in the study received platinum-based therapy before immunotherapy. Five (45.46%) patients received one prior therapy, 3 (27.27%) received two prior therapies, and 3 (27.27%) received three prior therapies.
Four (36.36%) of the patients had brain metastasis.
Two (18.18%) of the patients were more than 70 years of age [ Table 2 ].
All patients included in the analysis received at least six cycles of nivolumab at the standard dose of 3 mg/kg of body weight every 2 weeks. The median number of cycles of nivolumab administered was ten (range, 6-21).
At the time of analysis, the median PFS was 8 months (95% confidence interval [CI], 1.52-14.47) and median OS was 15 months (95% CI, 6.9-23.09) [ Figure 1a and b].
Response rates
Among 11 patients studied, 1 (9.09%) had complete response (CR), 2 (18.18%) partial response, 3 (27.27%) stable disease, and 5 (45.45%) progressive disease [ Table 3 ].
Adverse events
Pruritus was the most common side effect, seen in 8 (72.73%) of 11 patients. Fatigue and hypothyroidism were seen in 6 of 11 patients (54.55%). Two of 11 patients (18.18%) developed Grade 3-4 pneumonitis. Both these patients, despite the prolonged hospital stay and high-dose corticosteroids, did not recover from Grade 3-4 pneumonitis [ Table 4 ].
Discussion
Limited progress, related to second-line therapy in NSCLC, has been made since the approval of docetaxel as second-line chemotherapy for metastatic lung cancer. Despite the increased number of treatment options for NSCLC, survival remains poor. PDL-1 inhibitors have emerged as the new standard of care for the second-line treatment of NSCLC. In addition, pembrolizumab has been approved for patients with metastatic NSCLC, having PDL-1 expression of more than or equal to 50%. small, our data support the use of nivolumab as a new treatment option for patients of stage four NSCLC.
The median PFS was 8 months (95% CI, 1.52-14.47) and median OS was 15 months (95% CI, 6.9-23.09) in our study, which was more than the CheckMate studies, probably because all patients in our study had good performance status (ECOG 1), sample size was small, unselected nonclinical trial population and was a retrospective study.
Conclusion
Nivolumab proved its meaningful survival benefit in clinical practice since the effectiveness appears to be higher in this unselected nonclinical trial population as compared to the results of the clinical trials. Although our sample size was (Letter to the editor continue from page 46...)
distal interphalangeal joint involvement. [8] Most of these patients respond to bortezomib-based therapy. In the case report published by Patil and Oak, both patients who were diagnosed with amyloid arthropathy responded well to bortezomib and dexamethasone chemotherapy regimen. [11] In the case series by Srinivasulu et al., 3 of the 6 patients were treated with the bortezomib-based regimen. [10] Similarly, many other cases
